Abstracts tagged "biomarkers and rheumatoid arthritis (RA)"

Abstract Number: 1900 • 2017 ACR/ARHP Annual Meeting
Effect of Age and Body Mass Index (BMI) on Multi-Biomarker Disease Activity (MBDA) Score in Patients with Rheumatoid Arthritis
Kerri Ford¹, David Chernoff¹, Xingbin Wang¹, Eric H. Sasso¹, Carol J. Etzel^2,3 and Dimitrios A. Pappas^3,4, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴Columbia University, New York, NY
Background/Purpose: We evaluated the associations between MBDA score and age and between MBDA score and BMI in patients with rheumatoid arthritis (RA). These relationships may…
Abstract Number: 2868 • 2017 ACR/ARHP Annual Meeting
Pharmacodynamic Analysis of Whole Blood Gene Expression over 2 Years in a Phase IIIb Head-to-Head Trial of Abatacept and Adalimumab in Patients with RA
O Jabado¹, MA Maldonado¹, Michael Schiff², Michael Weinblatt³, Roy Fleischmann⁴, William H. Robinson⁵, A Greenfield¹ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women’s Hospital, Boston, MA, ⁴Metroplex Clinical Research Center Dallas, Dallas, TX, ⁵Stanford University, Palo Alto, CA
Background/Purpose: The head-to-head AMPLE study compared the safety and efficacy of abatacept (co-stimulatory modulator) versus adalimumab (TNFα inhibitor) for treatment of RA over 2 years.…
Abstract Number: 2648 • 2016 ACR/ARHP Annual Meeting
Predictive Role of Biomarkers for the Response to Biologic Therapy in Rheumatoid Arthritis. Old, New and How Future Looks like?
Bogdan Ion Gavrila¹, Claudia Ciofu², Victor Stoica³, Cornel Ursaciuc⁴, Dan Ciotaru⁴, Mihaela Surcel⁵, Adriana Munteanu⁴ and Eugenia Panaitescu⁶, ¹Internal Medicine and Rheumatology, Department of Internal Medicine and Rheumatology Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Bucharest, Romania, ²Department of Internal Medicine and Rheumatology Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Bucharest, Romania, ³Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ⁴INCD ,,Victor Babeș’’, Bucharest, Romania, Bucharest, Romania, ⁵INCD ,,Victor Babeș’’, Bucharest, Romania, bucharest, Romania, ⁶Carol Davila University of Medicine and Pharmacy ,Medical Informatics and Biostatistics, Bucharest, Romania
Background/Purpose: discovery of biomarkers that can identify pretreatment patients who will respond to biologic DMARDs therapy is one of the major interests in RA. We…
Abstract Number: 505 • 2016 ACR/ARHP Annual Meeting
The Longitudinal Stability of the RA Biomarkers RF and ACPA in Classifying RA Subtypes over Extended Follow up
Carl Orr, Francis Young and Douglas J. Veale, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland
Background/Purpose: In recent years several studies suggest that first order stratification of RA should be based on the presence or absence of rheumatoid factor (RF)…
Abstract Number: 556 • 2016 ACR/ARHP Annual Meeting
Higher Multi Biomarker Disease Activity Scores Foreshadow Greater Longitudinal Improvement in RA Disease Activity
Jeffrey Curtis¹, Leslie Harrold², Joel Kremer³ and J. Lynn Palmer⁴, ¹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²U Massachusetts, Worcester, MA, ³Albany Medical Center, Albany, NY, ⁴Corrona Research Foundation, Albany, NY
Background/Purpose: Biomarkers in patients with rheumatoid arthritis (RA) have the attractive potential to help select patients that have a greater burden of disease activity and…
Abstract Number: 651 • 2016 ACR/ARHP Annual Meeting
Calprotectin Serum Levels Strongly Predict Disease Flare in RA and Psa Patients with Low Disease Activity Treated with TNF Inhibitors. a One-Year Prospective Cohort Study
Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Virginia Ruiz-Esquide¹, Sonia Cabrera-Villalba¹, Julio Ramirez¹, Andrea Cuervo¹, Mariona Pascal², Jordi Yagüe², Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: An increasing number of RA and PsA patients achieve low levels of disease activity under biological therapy. Thus, new biomarkers are needed to stratify…
Abstract Number: 916 • 2016 ACR/ARHP Annual Meeting
Novel Immunosignature Stratifies Patients with Rheumatoid Arthritis into Distinct Disease Sub-Groups and Predicts Response to Anti-Tnfα Therapies
Laura Magill¹, Marsilio Adriani¹, Victoria Howard², Jessica Manson², Elizabeth Jury³ and Claudia Mauri⁴, ¹University College London, London, United Kingdom, ²University College London Hospitals NHS Trust, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Division of Medicine, Centre for Rheumatology Research, University College London, University College London, London, United Kingdom
Background/Purpose: Autoimmune rheumatic diseases, including rheumatoid arthritis (RA), have multifactorial pathogenesis associated with failure of immune tolerance. Advances in understanding the disease immunopathology have led…
Abstract Number: 1492 • 2016 ACR/ARHP Annual Meeting
Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis: A Population-Based Study
Jeffrey Curtis¹, Fenglong Xie², Lang Chen² and Huifeng Yun³, ¹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Serious infection events (SIE) and myocardial infarction (MI) are among the most concerning adverse events that occur in rheumatoid arthritis (RA) patients. The role…
Abstract Number: 1628 • 2016 ACR/ARHP Annual Meeting
Distinct Baseline Serum Molecular Profile and Pharmacodynamic Effects of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Asian-Pacific Patients with Active Rheumatoid Arthritis Despite DMARD or Anti-Tnfα Therapy Across Two Global Phase 3 Trials
Bidisha Dasgupta¹, Alice Walsh¹, Kristen Sweet¹, Nancy Peffer¹, Carol Franks¹, Keying Ma¹, Martin Sims², Kim Campbell¹ and Matthew Loza¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Baseline differences in rheumatoid arthritis (RA) disease characteristics and molecular profile across populations may be a reflection of genetic variations and environmental factors such…
Abstract Number: 1630 • 2016 ACR/ARHP Annual Meeting
Consistent Pharmacodynamic Effects of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Serum Analytes Across Four Phase 3 Clinical Trials in Rheumatoid Arthritis
Matthew Loza¹, Kristen Sweet¹, Nancy Peffer¹, Carol Franks¹, Keying Ma¹, Kim Campbell¹, Martin Sims² and Bidisha Dasgupta¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: The efficacy of sirukumab, an anti-IL-6 cytokine antibody, was evaluated in multiple phase 3 studies in patients with rheumatoid arthritis (RA) (SIRROUND -M, -D,…
Abstract Number: 2615 • 2016 ACR/ARHP Annual Meeting
Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors
Cem Gabay¹, Jérôme Msihid², Nikki Daskalakis³, Anne Barbot⁴, Moshe Zilberstein³ and Anita Boyapati⁵, ¹University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland, ²Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, NJ, France, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, France, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Patients with RA develop bone and joint damage due to chronic synovial inflammation that is mediated by specific cytokines.1 Cytokines (eg, IL-6) recruit activated…
Abstract Number: 2616 • 2016 ACR/ARHP Annual Meeting
The JAK1-Selective Inhibitor Filgotinib Displays an Anti-Inflammatory Biomarker Signature in Rheumatoid Arthritis Patients
Peter C. Taylor¹, R Westhovens², Luc Meuleners³, Birgen Meuleman⁴, Yang Pan⁵, Veerle Vyncke³, Annegret Van der Aa³, Pille Harrison³, Chantal Tasset³ and René Galien⁶, ¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³Galapagos NV, Mechelen, Belgium, ⁴2Bridge, Turnhout, Belgium, ⁵Gilead Sciences, Foster City, CA, ⁶102 Avenue Gaston Roussel, Galapagos SASU, Romainville, France
Methods : Patients with active RA on stable dose of MTX were randomized 1:1:1:1:1:1:1 in a double blind manner to receive either placebo (PBO) or…
Abstract Number: 2626 • 2016 ACR/ARHP Annual Meeting
Soluble CD206 Plasma Levels Decreases with Treatment and Reflects Anti-Tnfa Discontinuation in Rheumatoid Arthritis
Line Dam Heftdal^1,2, Kristian Stengaard-Pedersen², Merete Lund Hetland^3,4, Kim Hørslev-Petersen⁵, Peter Junker⁶, Mikkel Østergaard^4,7, Malene Hvid^8,9, Bent Deleuran^2,8,9, Holger Jon Møller^8,10 and Stinne Greisen^2,9, ¹Department of Biomedicine, Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, Copenhagen, Denmark, ⁵King Christian X's Hospital for Rheumatic Diseases,, University of Southern Denmark, Graasten, Denmark, ⁶Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁸Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ¹⁰Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovial joints and infiltration by activated macrophages. TNFa is a central…
Abstract Number: 2634 • 2016 ACR/ARHP Annual Meeting
Lack of Autoantibodies to Peptidyl Arginine Deiminase 4 Predict Increased Efficacy of Mavrilimumab in Rheumatoid Arthritis
Ethan Grant¹, Martin Schwickart², Alex Godwood³, Rachel Moate³, Esther Song², Carlos Chavez², Marius Albulescu⁴, David Close⁴, Meina Liang², Tomas Mustelin⁵, Zhengbin Yao⁶ and Koustubh Ranade¹, ¹Translational Medicine, MedImmune, Gaithersburg, MD, ²Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, MD, ³MedImmune, Cambridge, United Kingdom, ⁴Clinical Development, MedImmune, Cambridge, United Kingdom, ⁵Respiratory, Inflammation and Autoimmunity, MedImmune, Gaithersburg, MD, ⁶Respiratory, Inflammation and Autoimmunity iMED, MedImmune, Gaithersburg, MD
Background/Purpose: Mavrilimumab is an anti-GM-CSF receptor Ab that has recently demonstrated clinical efficacy in Phase 2 studies in rheumatoid arthritis (RA) patients. Predictive biomarkers to…
Abstract Number: 1244 • 2015 ACR/ARHP Annual Meeting
Extracellular MicroRNAs in Synovial Fluid Reveal a Marked Proliferative Signature in Patients with Antibiotic-Refractory Lyme Arthritis
Robert B. Lochhead, Nancy D. Kim, Sheila Arvikar, Klemen Strle and Allen C. Steere, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Lyme arthritis (LA), caused by a tick-borne spirochete Borrelia burgdorferi, usually resolves appropriately with antibiotic treatment, called antibiotic-responsive LA. However, in some patients, arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.